Could this pill ease Alzheimer's psychosis? large trial underway

NCT ID NCT06947941

Recruiting now Symptom relief Sponsor: Bristol-Myers Squibb Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jul 01, 2026 · Updated 4 times

Summary

This Phase 3 trial tests whether the drug combination KarXT + KarX-EC can safely reduce psychosis symptoms (like hallucinations and delusions) in people with Alzheimer's disease. About 325 participants aged 55-90 will receive either the drug or a placebo. The study is currently recruiting.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: KarXT (xanomeline/trospium chloride) plus KarX-EC (xanomeline enteric-coated)
What this could lead to: If successful, this could provide a new treatment option to ease psychosis symptoms like hallucinations and delusions in people with Alzheimer's disease.
What could go wrong: This is an early Phase 3 trial, so results are not guaranteed. The drug may not work better than placebo, and side effects are possible. It is not a cure for Alzheimer's.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Alzheimer disease dementia psychotic disorder Psychotic Disorders

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ALZHEIMER DISEASE PSYCHOSIS

Contacts and locations

Locations

Gilbert Neurology Partners/CCT Research
RECRUITING

Gilbert, Arizona, 85297, United States
Inland Psychiatric Medical Group.
RECRUITING

Chino, California, 91710, United States
Insight Clinical Trials LLC - Independence
RECRUITING

Independence, Ohio, 44131, United States
Local Institution - 0001
WITHDRAWN

Naples, Florida, 34105, United States
Local Institution - 0004
NOT_YET_RECRUITING

Motherwell, ML1 4UF, United Kingdom
Local Institution - 0005
NOT_YET_RECRUITING

Exeter, Devon, EX12LU, United Kingdom
Local Institution - 0009
NOT_YET_RECRUITING

Chertsey, Surrey, KT160PZ, United Kingdom
Local Institution - 0015
WITHDRAWN

Oxford, Oxfordshire, OX3 7JX, United Kingdom
Local Institution - 0017
NOT_YET_RECRUITING

Sheffield, Yorkshire and the Humber, S47QQ, United Kingdom
Local Institution - 0018
WITHDRAWN

Crowborough, TN6 1NY, United Kingdom
Local Institution - 0020
NOT_YET_RECRUITING

Macquarie Park, New South Wales, 2113, Australia
Local Institution - 0023
NOT_YET_RECRUITING

London, England, W1G 8TA, United Kingdom
Local Institution - 0024
NOT_YET_RECRUITING

London, WC1N3BG, United Kingdom
Local Institution - 0025
NOT_YET_RECRUITING

Montreal, Quebec, H4H 1R3, Canada
Local Institution - 0027
NOT_YET_RECRUITING

Whitby, Ontario, L1N 5S9, Canada
Local Institution - 0029
NOT_YET_RECRUITING

Cleveland, Ohio, 44195, United States
Local Institution - 0034
NOT_YET_RECRUITING

Osaka, 550-0006, Japan
Local Institution - 0035
NOT_YET_RECRUITING

Nankoku-shi, 783-8505, Japan
Local Institution - 0040
NOT_YET_RECRUITING

Suita, Osaka, 565-0871, Japan
Local Institution - 0052
NOT_YET_RECRUITING

Nedlands, Western Australia, 6009, Australia
Local Institution - 0054
NOT_YET_RECRUITING

Toronto, Ontario, M6J1H4, Canada
Local Institution - 1401
NOT_YET_RECRUITING

Naples, Florida, 34105, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.